<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973449</url>
  </required_header>
  <id_info>
    <org_study_id>D7220C00001</org_study_id>
    <nct_id>NCT04973449</nct_id>
  </id_info>
  <brief_title>Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults</brief_title>
  <acronym>AZD2816</acronym>
  <official_title>A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the&#xD;
      prevention of COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the safety and characterize the immunogenicity of&#xD;
      AZD2816; AstraZeneca's candidate ChAdOx1 vector vaccine against SARS-CoV-2 variant strain&#xD;
      B.1.351&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2021</start_date>
  <completion_date type="Anticipated">July 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Previously vaccinated individuals will receive 1 dose of AZD1222 or AZD2816 on Day 1. Previously unvaccinated participants will receive one of the following 2-dose vaccinations:&#xD;
1 dose of AZD2816 on Day 1 and on Day 29&#xD;
1 dose of AZD1222 on Day1 and on Day 29&#xD;
1 dose of AZD1222 on Day 1 and 1 dose of AZD2816 on Day 29&#xD;
1 dose of AZD2816 on Day 1 and on Day 85. Participants will be followed up for safety for 180 days after last study vaccine administration.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind: two or more parties are unaware of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of 1 dose of AZD2816 in the previously vaccinated cohort with AZD1222</measure>
    <time_frame>for 7 days</time_frame>
    <description>Incidence of local and systemic solicited AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of 1 dose of AZD2816 in the previously vaccinated cohort with AZD1222</measure>
    <time_frame>28 days post dose</time_frame>
    <description>The change from baseline for safety laboratory measures&#xD;
Incidence of unsolicited AEs, including MAAEs, SAEs, and AESIs,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of a 2-dose primary vaccination with AZD2816 in the unvaccinated cohort</measure>
    <time_frame>for 7 days</time_frame>
    <description>Incidence of local and systemic solicited AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of a 2-dose primary vaccination with AZD2816 in the unvaccinated cohort</measure>
    <time_frame>28 days post dose</time_frame>
    <description>The change from baseline for safety laboratory measures&#xD;
Incidence of unsolicited AEs, including MAAEs, SAEs, and AESIs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine if the response against B.1.351 elicited by an AZD2816 booster dose in participants previously vaccinated with AZD1222 is non-inferior to the response against Wuhan-Hu-1 strain elicited by 2-dose AZD1222 administered to naïve participants</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies for AZD2816 booster/AZD1222 vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine if the response against the B.1.351 variant elicited by a 2-dose AZD2816 vaccination is non-inferior to the response against the original Wuhan-Hu-1 strain elicited by a 2-dose AZD1222 vaccination in the unvaccinated cohort</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies for AZD2816 vaccination/AZD1222 Vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if seroresponse against the B.1.351 variant elicited by a 2-dose AZD2816 vaccination is non-inferior to seroresponse against the original WuHan-hu-1 strain elicited by a 2-dose AZD1222 vaccination in the unvaccinated cohort</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>Difference in seroresponse rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the neutralizing antibody GMT response against the B.1.351 variant elicited by a 2-dose AZD2816 vaccination is non-inferior to the response elicited by a 2-dose AZD1222 vaccination in the unvaccinated cohort</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the response against the B.1.351 variant elicited by AZD1222 + AZD2816 vaccination is non-inferior to the response against the Wuhan-Hu-1 strain elicited by AZD1222 in the unvaccinated cohort</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the neutralizing antibody GMT response against the original Wuhan-Hu-1 elicited by a 2-dose AZD2816 vaccination is non-inferior to the response elicited by a 2-dose AZD1222 vaccination</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the response against B.1.351 elicited by an AZD2816 booster dose in participants previously vaccinated with AZD1222 is non-inferior to the response elicited by 2-dose AZD1222 vaccination administered to vaccination naïve participants</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies&#xD;
Difference in seroresponse rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the humoral immune response elicited against the B.1.351 variant by an AZD2816 booster dose is non-inferior to the response elicited by an AZD1222 booster dose in participants previously vaccinated with AZD1222</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies&#xD;
Difference in seroresponse rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the response against the WuHan-hu-1 strain elicited by an AZD2816 booster in participants previously vaccinated with AZD1222 is non-inferior to the response elicited by 2-dose AZD1222 administered to vaccination naïve participants</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies&#xD;
Difference in seroresponse rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the humoral immune response against the original WuHan-hu-1 strain elicited by an AZD1222 booster dose in participants previously vaccinated with AZD1222 is non-inferior to the response elicited by a 2-dose AZD1222 vaccination</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies&#xD;
Difference in seroresponse rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if the humoral immune response against the original WuHan-hu-1 strain elicited by an AZD2816 booster dose is non-inferior to the response elicited by an AZD1222 booster dose in participants previously vaccinated with AZD1222</measure>
    <time_frame>28 days post second dose</time_frame>
    <description>GMT ratio of pseudoneutralizing antibodies</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">2849</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>ChAdOx1-S booster: one dose of AZD1222</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously vaccinated with AZD1222, dosing on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChAdOx1-S booster: one dose of AZD2816</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously vaccinated with AZD1222, dosing on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA booster: one dose of AZD1222</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously vaccinated with an mRNA vaccine, dosing on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA booster: one dose of AZD2816</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously vaccinated with an mRNA vaccine, dosing on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of AZD1222, 4 weeks apart</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously unvaccinated. First dose day 1, second dose day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of AZD2816, 4 weeks apart</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously unvaccinated. First dose day 1, second dose day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of AZD2816, 12 weeks apart</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously unvaccinated. First dose day 1, second dose day 85</description>
  </arm_group>
  <arm_group>
    <arm_group_label>one dose of AZD1222 + one dose AZD2816, 4 weeks apart</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously unvaccinated. Dose of AZD1222 on day 1, dose of AZD2816 on day 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD1222</intervention_name>
    <description>10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.</description>
    <arm_group_label>2 doses of AZD1222, 4 weeks apart</arm_group_label>
    <arm_group_label>ChAdOx1-S booster: one dose of AZD1222</arm_group_label>
    <arm_group_label>mRNA booster: one dose of AZD1222</arm_group_label>
    <arm_group_label>one dose of AZD1222 + one dose AZD2816, 4 weeks apart</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD2816</intervention_name>
    <description>10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6</description>
    <arm_group_label>2 doses of AZD2816, 12 weeks apart</arm_group_label>
    <arm_group_label>2 doses of AZD2816, 4 weeks apart</arm_group_label>
    <arm_group_label>ChAdOx1-S booster: one dose of AZD2816</arm_group_label>
    <arm_group_label>mRNA booster: one dose of AZD2816</arm_group_label>
    <arm_group_label>one dose of AZD1222 + one dose AZD2816, 4 weeks apart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult, ≥ 18 years of age at the time of consent&#xD;
&#xD;
             For inclusion in the SARS-CoV-2 seronegative population:&#xD;
&#xD;
          2. No history of laboratory-confirmed SARS-CoV-2 infection (ie, no positive nucleic acid&#xD;
             amplification test and no positive antibody test).&#xD;
&#xD;
          3. Seronegative for SARS-CoV-2 at screening (lateral flow test to detect reactivity to&#xD;
             the nucleoprotein).&#xD;
&#xD;
          4. Medically stable such that, according to the judgment of the investigator,&#xD;
             hospitalization within the study period is not anticipated and the participant appears&#xD;
             likely to be able to remain on study through the end of protocol-specified follow-up&#xD;
&#xD;
          5. Able to understand and comply with study requirements/procedures (if applicable, with&#xD;
             assistance by caregiver, surrogate, or legally authorized representative) based on the&#xD;
             assessment of the investigator&#xD;
&#xD;
          6. Signed informed consent obtained before conducting any study-related procedures&#xD;
&#xD;
          7. Contraceptive use by women should be consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies.&#xD;
&#xD;
             Previously COVID-19 Vaccinated Participants:&#xD;
&#xD;
          8. Prior completion of a 2-dose primary homologous vaccination regimen against SARSCoV-2&#xD;
             with either AZD1222 (2 standard doses as authorized vaccine or as investigational&#xD;
             product in a clinical trial with a 4 to 12-week dosing interval) or with an mRNA&#xD;
             vaccine approved for emergency or conditional use. The second dose in all cases should&#xD;
             have been administered at least 3 months prior to first administration of study&#xD;
             intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to any component of AZD1222/AZD2816.&#xD;
&#xD;
          2. History of Guillain-Barré syndrome, any demyelinating disease, or any other&#xD;
             neuroimmunologic condition&#xD;
&#xD;
          3. Significant infection or other acute illness, including fever &gt; 100 °F (&gt; 37.8 °C) on&#xD;
             the day prior to or day of randomization&#xD;
&#xD;
          4. Any confirmed or suspected immunosuppressive or immunodeficient state, including&#xD;
             asplenia or HIV/AIDS.&#xD;
&#xD;
          5. Recurrent severe infections and use of immunosuppressant medication within the past 6&#xD;
             months (≥ 20 mg per day of prednisone or its equivalent, given daily or on alternate&#xD;
             days for ≥ 15 days within 30 days prior to administration of study intervention). The&#xD;
             following exceptions are permitted: Topical/inhaled steroids or short-term oral&#xD;
             steroids (course lasting ≤ 14 days)&#xD;
&#xD;
          6. History of primary malignancy (see protocol)&#xD;
&#xD;
          7. History of thrombocytopenia and/or thrombosis, including participants who have&#xD;
             experienced major venous and/or arterial thrombosis in combination with&#xD;
             thrombocytopenia following vaccination with any COVID-19 vaccine&#xD;
&#xD;
          8. History of heparin-induced thrombocytopenia, congenital thrombophilia (ie, factor V&#xD;
             Leiden, prothrombin G20210A, antithrombin III deficiency, protein C deficiency and&#xD;
             protein S deficiency, factor XIII mutation, familial dysfibrinogenemia), auto-immune&#xD;
             thrombophilia (antiphospholipid syndrome, anti-cardiolipin antibodies, anti-β2-&#xD;
             glycoprotein 1 antibodies), or paroxysmal nocturnal haemoglobinuria.&#xD;
&#xD;
          9. Clinically significant bleeding (eg, factor deficiency, coagulopathy, or platelet&#xD;
             disorder), or prior history of significant bleeding or bruising following&#xD;
             intramuscular injections or venepuncture&#xD;
&#xD;
         10. Severe and/or uncontrolled cardiovascular disease, respiratory disease,&#xD;
             gastrointestinal disease, liver disease, renal disease, endocrine disorder, or&#xD;
             neurological illness, as judged by the Investigator&#xD;
&#xD;
         11. Any other significant disease, disorder, or finding that may significantly increase&#xD;
             the risk to the participant because of participation in the study, affect the ability&#xD;
             of the participant to participate in the study, or impair interpretation of the study&#xD;
             data&#xD;
&#xD;
         12. Any autoimmune conditions, except mild psoriasis and vitiligo.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>115 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasilia</city>
        <zip>70200-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80810-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Natal</city>
        <zip>59020-035</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Natal</city>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oświęcim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skórzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS105NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2KZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E2 0HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2QW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7EJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO1 3HN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure&#xD;
URL:&#xD;
https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

